AmifostineThird Party Manufacturing in India

Amifostine is a prodrug cytoprotective agent that selectively protects normal tissues from the toxic effects of cisplatin chemotherapy and radiation therapy. It is an organic thiophosphate compound administered intravenously before chemotherapy or radiation. Once in the body, amifostine is dephosphorylated by membrane-bound alkaline phosphatase — an enzyme found in significantly higher concentrations in healthy tissues compared to tumor tissues. This enzymatic conversion produces the active free thiol metabolite known as WR-1065. The active metabolite works through two primary mechanisms. First, it binds directly to and detoxifies reactive platinum-containing metabolites of cisplatin, preventing them from forming damaging DNA adducts in healthy cells. Second, it acts as a potent free radical scavenger, neutralizing the reactive oxygen species generated by both cisplatin and ionizing radiation. Because healthy tissues have better blood perfusion, higher alkaline phosphatase activity, and a more favorable pH than tumor tissues, they convert amifostine to its active form more rapidly. Normal cells concentrate the active metabolite at levels up to 100-fold higher than cancer cells. This selective uptake allows normal tissues — particularly the kidneys and salivary glands — to be protected without reducing the antitumor efficacy of the treatment.

Amifostine is a specialized cytoprotective adjuvant used in oncology to reduce specific toxicities associated with cisplatin chemotherapy and radiation therapy. It is available as a sterile lyophilized powder for injection in 500 mg/vial strength.

Therapeutic Uses

• Cisplatin-Induced Nephrotoxicity: Reduces cumulative renal toxicity from repeated cisplatin administration in patients with advanced ovarian cancer and non-small cell lung cancer. Administered as a 15-minute IV infusion 30 minutes before chemotherapy
• Radiation-Induced Xerostomia: Decreases the incidence and severity of moderate to severe dry mouth in patients undergoing post-operative radiation therapy for head and neck cancer when the parotid glands are in the radiation field
• Orphan Indications: Investigated for chemoprotection in cisplatin treatment for metastatic melanoma, cyclophosphamide therapy in ovarian carcinoma, and reduction of toxicities from other alkylating agents

Why Manufacturers Choose Amifostine

Amifostine is a high-value specialty injectable with consistent demand from oncology centers and hospital pharmacies. As the only FDA-approved broad-spectrum cytoprotectant for cisplatin-induced nephrotoxicity, it occupies a unique position in the oncology supportive care market. Indian manufacturers with WHO-GMP certified sterile injectable facilities and advanced lyophilization capabilities can serve both domestic hospital demand and regulated export markets. The 500 mg/vial presentation is the global standard dosage form, and production requires expertise in aseptic processing and lyophilization.

This makes Amifostine one of the sought-after molecules for third party manufacturing in India, with consistent demand from institutional buyers and export-oriented pharmaceutical companies.